Parabilis Medicines (PBLS) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Parabilis Medicines (PBLS) is Moderate Underperform.

The composite score behind that read is -0.27, weighing +0.83 of bullish evidence against -0.37 bearish.

Parabilis Medicines last closed at $28.86, -2.27% on the session.

Against the IVW growth benchmark the position is -2.11% over the forecast window.

The read is built from 11 underlying insights — 1 bullish and 10 bearish.

Agreement across those insights is 91%.

17 graded predictions for PBLS so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

Parabilis Medicines is classified under Health Care / Biotechnology, with a market capitalisation of $3.52B.

StockMap tracks Parabilis Medicines as the 64th largest of the 377 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 198 Moderate Underperform, 166 Neutral and 13 Strong Underperform.

On that composite Parabilis Medicines ranks 252nd of 377 in the group, against a group median of -0.21.